Research and Development

Takeda has announced data from the phase 3 ADVANCE-CIDP 3 trial, which assessed the safety and efficacy of Hyqvia (Immune …

Assembly Biosciences has announced that the first participant has been dosed in its phase 1b trial of ABI-4334, the company’s …

Innate Pharma has announced updated efficacy and safety results from the dose-escalation part of the phase 1/2 study with SAR443579/IPH6101 …

AbbVie and FutureGen Biopharmaceutical have announced a license agreement for the development of FG-M701, a next-generation TL1A antibody for the …

Pfizer has announced an update from its phase 3 randomised, multicentre, double-blind, placebo-controlled CIFFREO trial, which assessed the investigational mini-dystrophin …

Cara Therapeutics has announced the outcome from the dose-finding Part A of the KOURAGE-1 study which assessed the efficacy and …

Evotec has announced that it has reached important scientific progress within the neuroscience collaboration with Bristol Myers Squibb, initiating a …

Eli Lilly has announced results from the phase 2 SYNERGY-NASH study which assessed 190 patients, with or without type 2 …

Nuclera has announced that it has been awarded two grants from Innovate UK, totalling £1.14m.

Syngene has announced the launch of its new protein production platform, which will utilise a cell line and transposon-based technology …

Gilead has announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary …

Sanofi has announced data from the IMROZ phase 3 trial which assessed Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide …

Gilead Sciences and Arcus Biosciences have announced new data from cohort B of ARC-9, a phase 1b/2 study which aims …

OSE Immunotherapeutics and Boehringer Ingelheim have announced a major expansion of their existing partnership. The expansion includes two new projects …

Nona Biosciences and AstraZeneca have announced that the two companies have entered into a license agreement for preclinical monoclonal antibodies, …